share_log

Cooper Companies | 8-K: CooperCompanies Announces Third Quarter 2024 Results

Cooper Companies | 8-K: CooperCompanies Announces Third Quarter 2024 Results

库珀医疗 | 8-K：库珀公司公布2024年第三季度业绩
美股SEC公告 ·  2024/08/29 04:23

Moomoo AI 已提取核心信息

Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.
Cooper Companies reported strong Q3 FY2024 results with revenue increasing 8% YoY to $1,002.8 million. CooperVision revenue grew 7% to $675.6 million, while CooperSurgical revenue rose 9% to $327.2 million. GAAP diluted EPS increased 22% to $0.52, and non-GAAP diluted EPS grew 14% to $0.96.Operating performance showed improvement with non-GAAP operating margin expanding to 26% from 24% last year, driven by gross margin gains and SG&A leverage. The company generated free cash flow of $118.5 million after capital expenditures of $89.0 million.Based on strong performance, Cooper raised its fiscal 2024 guidance, now projecting total revenue of $3,892-$3,913 million with 8-8.5% organic growth. The company expects non-GAAP diluted EPS of $3.64-$3.67 for the full year, demonstrating continued momentum in its growth strategy.
库珀医疗公布了2024财年第三季度强劲业绩，营业收入同比增长8%，达到100280万美元。库珀视觉的营业收入增长7%，达到67560万美元，而库珀外科的营业收入增长9%，达到32720万美元。GAAP摊薄后每股收益增长22%，达到0.52美元，非GAAP摊薄后每股收益增长14%，达到0.96美元。营业绩效有所改善，非GAAP营业利润率从去年的24%扩大至26%，主要受益于毛利率的增加和销售及管理费用的杠杆效应。该公司在8900万美元的资本支出后，产生了11850万美元的自由现金流。基于强劲的业绩，库珀提高了2024财年的指导，现在预计总营业收入为3892-391300万美元， organic growth为8-8.5%。公司预计全年的非GAAP摊薄后每股收益为3.64-3.67美元，显示出其增长策略的持续动能。
库珀医疗公布了2024财年第三季度强劲业绩，营业收入同比增长8%，达到100280万美元。库珀视觉的营业收入增长7%，达到67560万美元，而库珀外科的营业收入增长9%，达到32720万美元。GAAP摊薄后每股收益增长22%，达到0.52美元，非GAAP摊薄后每股收益增长14%，达到0.96美元。营业绩效有所改善，非GAAP营业利润率从去年的24%扩大至26%，主要受益于毛利率的增加和销售及管理费用的杠杆效应。该公司在8900万美元的资本支出后，产生了11850万美元的自由现金流。基于强劲的业绩，库珀提高了2024财年的指导，现在预计总营业收入为3892-391300万美元， organic growth为8-8.5%。公司预计全年的非GAAP摊薄后每股收益为3.64-3.67美元，显示出其增长策略的持续动能。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Zentek
    ZTEK
    -- 1.180
    Glucotrack
    GCTK
    -- 0.0849
    Daxor
    DXR
    -- 8.500
    Envista Holdings
    NVST
    -- 19.830
    美华国际
    MHUA
    -- 0.325

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    特朗普2.0机会预览：在总统上任前猜出市场赢家！